2017: A Big Year for AbSci – Growth and Continued Expansion

2017: A Big Year for AbSci – Growth and Continued Expansion

AbSci, a global leader in breakthrough biomanufacturing technologies, today announced that it is further expanding its offices and laboratory facilities. “We’ve seen a significant increase in partnership deal flow, which is a testament to the innovation and quality of work performed by our scientists,” said CEO and Founder, Sean McClain …

read more
AbSci wins 2017 OEN ‘Start-up’ Award

AbSci wins 2017 OEN ‘Start-up’ Award

Oct 26, 2017. Companies in biotech, security software and cloud management were among the big winners Wednesday night at the 24th Annual OEN Tom Holce Entrepreneurship Awards.Hundreds of Oregon business community members turned out for the event at the Oregon...

read more
AbSci Raises Series B Financing

AbSci Raises Series B Financing

AbSci, a global leader in breakthrough biomanufacturing technologies, announced that it closed its Series B financing round for an undisclosed amount. The round includes previous investors along with several new investors …

read more
US Patent Granted for SoluPro™ Technology

US Patent Granted for SoluPro™ Technology

Vancouver, WA – April 11, 2017 United States Patent No. 9,617,335 was issued today to AbSci, an industry leader in biomanufacturing innovation, for its SoluPro™ protein expression system, which produces complex therapeutic proteins at unparalleled yield and throughput...

read more
AbSci Receives European Patent on its SoluPro™ Expression Platform

AbSci Receives European Patent on its SoluPro™ Expression Platform

AbSci a global leader in biomanufacturing technologies, was granted a European regional patent today for its SoluPro™ protein production technology. “Many years of discovery went into developing the SoluPro™ expression platform. The SoluPro™ technology provides a revolutionary solution to one of biomanufacturing’s ongoing challenges …

read more
AbSci Announces New Headquarters in Downtown Vancouver Washington

AbSci Announces New Headquarters in Downtown Vancouver Washington

AbSci announced today that the company has finalized a lease agreement to relocate its headquarters to the new Hudson Building in downtown Vancouver, WA. AbSci expects to begin renovations by the beginning of September, and plans to take occupancy of the state-of-the-art lab facility by Q4 of this year, where the company will continue to develop and commercialize its revolutionary protein production technology.

read more